Analytical Tool - Lung Cancer

  • ID: 1196677
  • March 2014
  • Region: Global
  • Bioseeker
1 of 2

Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2014".

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. Updates are supplied for this report during the year. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Varian Medical Systems, Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Amgen Inc.
  • Almac Diagnostics Group
  • Boston Biomedical Inc.